Photobiomodulation uses red and near-infrared light to activate mitochondrial proteins, reduce inflammation, and promote tissue repair. Proper dosing and wavelength selection are essential for effective deep tissue penetration and anti-inflammatory effects. It is a safe, evidence-supported adjunct therapy primarily for pain relief, wound healing, and oral mucositis.
The anti-inflammatory light effect is photobiomodulation (PBM): the use of red and near-infrared light, typically in the 600–1100 nm range, to shift cell biochemistry away from inflammation and toward repair. It is not heat therapy, and it is not a cosmetic gimmick. At the right dose, specific wavelengths activate mitochondrial proteins, increase ATP output, and suppress the signalling molecules that drive chronic inflammation.
Here is what that means in practice:
Photobiomodulation is the clinically recognised term for what is often marketed as “red light therapy” or “infrared therapy.” The mechanism is real and peer-reviewed.
Wavelength determines depth. Red light (~630–700 nm) reaches skin and superficial tissue; near-infrared (~700–1100 nm) penetrates to muscle, joint, and even brain tissue.
Dose is everything. Too little light produces no effect; too much can inhibit healing. The therapeutic window is specific, and clinical-grade devices with documented irradiance are the only reliable way to stay inside it.
What is the anti-inflammatory light effect, exactly?
Photobiomodulation is the formal scientific term for what most people call red light therapy or low-level laser therapy (LLLT). The phrase “anti-inflammatory light effect” describes one of PBM’s most clinically significant outcomes: the measurable reduction in pro-inflammatory signalling that follows exposure to red or near-infrared light at non-thermal intensities.
The wavelength bands that produce this effect sit roughly between 600 nm and 1100 nm. Devices that deliver PBM include low-level lasers, LED panels, and flexible LED pads. Each format can produce therapeutic irradiance; the key variable is whether the device actually delivers the stated output at the treatment distance, not the form factor itself.
Two researchers whose work anchors the evidence base are worth knowing. Michael R. Hamblin, formerly of the Wellman Center for Photomedicine at Harvard, has authored or co-authored hundreds of peer-reviewed PBM papers, including foundational mechanistic reviews. A 2023 paper published in Frontiers in Neuroscience demonstrated cytokine-level anti-inflammatory effects in animal models, adding mechanistic weight to earlier clinical observations.
This article covers mechanisms, evidence quality, dosing parameters, safety, and practical device selection for Australian clinicians and informed consumers. It does not make cosmetic claims unsupported by clinical evidence.
Which molecules actually absorb the light?
Light cannot change cell behaviour unless something inside the cell absorbs it first. Those absorbing molecules are called chromophores, and identifying them is what separates PBM science from speculation.
Cytochrome c oxidase is the primary chromophore and the most important one to understand. It sits in the inner mitochondrial membrane as part of Complex IV of the electron transport chain — essentially the final step in the process your cells used to generate energy. When red or near-infrared photons are absorbed by cytochrome c oxidase, the enzyme’s activity increases, driving more ATP production and reducing the accumulation of reactive oxygen species (ROS) that would otherwise trigger inflammatory signalling. Think of it as unchaining a slightly sluggish engine: the light removes a brake on energy production.
Opsins are light-sensitive proteins found in non-retinal tissues, including skin and neurons. They may mediate calcium ion channel responses to red and near-infrared light.
Flavoproteins (flavins) absorb shorter wavelengths and play a role in redox signalling within mitochondria.
Haem proteins in the blood and tissue also absorb in the red range, potentially contributing to nitric oxide release and local vasodilation.
Structured water and ion channels: one emerging hypothesis, described in Scientific American, proposes that red and near-infrared light reduces intracellular water viscosity, improving the physical movement of enzymes and mitochondrial components. This remains a secondary hypothesis rather than established consensus.
Chromophore absorption is wavelength-specific. Cytochrome c oxidase absorbs most strongly in two bands: around 630–680 nm (red) and 800–880 nm (near-infrared). This is why PBM devices targeting deep tissue tend to use wavelengths in those ranges rather than arbitrary choices.
How absorbed light changes your cell biochemistry
The photon hits cytochrome c oxidase. What happens next is a cascade, not a single event, and understanding the sequence explains why PBM can reduce inflammation in tissues the light never directly touches.
Step one: mitochondrial stimulation. Increased cytochrome c oxidase activity accelerates the electron transport chain, producing more ATP. Cells with more ATP available can repair membranes, synthesise proteins, and regulate ion gradients more effectively — all processes that are compromised in inflamed or injured tissue.
Step two: the ROS signal. A brief, low-level burst of reactive oxygen species follows photon absorption. This sounds counterintuitive — ROS are usually framed as damaging — but at low concentrations they act as signalling molecules. This transient ROS pulse activates transcription factors including NF-κB and MAPK. PBM modulates NF-κB activation, and in pro-inflammatory tissue environments, that modulation tends to suppress rather than amplify the inflammatory response. The distinction matters: the same pathway that drives inflammation when chronically activated can be reset toward resolution by a well-dosed PBM stimulus.
Step three: cytokine shifts. The downstream result of NF-κB and MAPK modulation is a measurable change in cytokine expression. Pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and IL-18 are reduced; anti-inflammatory cytokines including IL-10 and TGF-β increase. These are not theoretical predictions — they have been measured in animal models and, increasingly, in human tissue samples.
Step four: systemic spread. Local PBM treatment does not stay local. Circulating cytokines and neural reflexes carry the anti-inflammatory signal systemically, which explains why treating one limb sometimes produces measurable effects elsewhere. This systemic dimension is one of the more surprising findings in PBM research and one of the reasons clinical protocols are becoming more sophisticated.
Key biochemical changes at a glance:
Increased ATP production via electron transport chain up regulation
Transient, low-level ROS burst acting as a signalling trigger
Suppression of NF-κB and MAPK in pro-inflammatory conditions
Reduced TNF-α, IL-1β, IL-6, and IL-18
Increased IL-10 and TGF-β
Nitric oxide release contributing to vasodilation and tissue perfusion
Why wavelength determines how deep the light reaches
Not all wavelengths behave the same way inside tissue. The physics of light scattering and absorption by water, haemoglobin, and melanin create a penetration window that is directly relevant to clinical decision-making.
Transcranial PBM, deep joint, visceral applications
Red light is absorbed more readily by haemoglobin and melanin, which limits its reach to superficial layers. Near-infrared light scatters less and penetrates further, making it the preferred choice for joint, muscle, and neurological targets. For skin conditions and superficial wound healing, red wavelengths around 630–660 nm are well-supported. For deeper structures — a knee joint, a lumbar muscle, or transcranial applications — 810–850 nm and above is where the evidence sits.
Devices that combine multiple wavelengths (sometimes called tri-wave devices) allow a single treatment session to address both superficial and deeper tissue simultaneously. The CelLED Pro Mini tri-wave pad from Lifespan Dynamics, for example, delivers 660 nm, 850 nm, and 940 nm in one flexible pad — covering the red band for surface tissue and two NIR bands for deeper penetration.
Pro Tip:When comparing devices, check whether the stated wavelength is the peak emission wavelength or the full-width half-maximum (FWHM) range. A device labelled “850 nm” should emit most of its energy within a narrow band around that peak, not across a broad spectrum that dilutes the therapeutic dose.
For a detailed comparison of red versus near-infrared applications, this wavelength guide is worth reading before choosing a device.
What does the clinical evidence actually show?
The evidence base for PBM’s anti-inflammatory effects spans in vitro cell studies, animal models, and human clinical trials. Quality and confidence vary by indication, so it is worth being specific.
Animal models have produced some of the clearest mechanistic data. A 2023 Frontiers in Neuroscience study demonstrated that red and near-infrared PBM downregulated IL-1β, IL-18, and upregulated IL-10 in a mouse inflammation model following ten days of exposure. Inflammasome modulation — the suppression of the protein complexes that trigger IL-1β and IL-18 release — is a plausible mechanism for the observed reductions in tissue inflammation and improved healing.
Human clinical evidence is strongest for three indications:
Pain reduction — multiple systematic reviews and meta-analyses report statistically significant reductions in musculoskeletal pain across conditions including neck pain, low back pain, and arthritis.
Oral mucositis — PBM has been included in treatment guidelines by NICE and other bodies for the prevention and management of chemotherapy-induced oral mucositis, one of the few areas where guideline adoption has occurred.
Wound healing — clinical trials show accelerated wound closure and reduced inflammatory markers in chronic wounds and post-surgical recovery.
Neuroinflammation and transcranial PBM are areas of active research with promising early data, but not yet the volume of randomised controlled trials needed for strong clinical recommendations.
“Photobiomodulation uses non-thermal red and near-infrared light to target mitochondria and increase ATP production, reducing oxidative stress and modulating inflammation — with the strongest human evidence concentrated in pain management, wound healing, and oral mucositis.” — Springer Nature umbrella review of randomised clinical trials, 2025
Michael R. Hamblin’s body of work, including his 2017 PMC review on mechanisms and applications of PBM’s anti-inflammatory effects, remains one of the most cited starting points for understanding the evidence hierarchy. His framing of cytochrome c oxidase as the primary chromophore and the biphasic dose response as a central clinical challenge has shaped how researchers and clinicians approach protocol design.
Why dose matters more than most people realise
The single most common reason PBM fails to produce results is incorrect dosing. Too little irradiance and the photons do not reach therapeutic threshold; too much and the biphasic dose response tips from stimulatory to inhibitory.
Key parameters to understand:
Irradiance (mW/cm²): the power density delivered to the tissue surface. This is the rate of energy delivery.
Fluence or dose (J/cm²): the total energy delivered per unit area. Calculated as irradiance × time in seconds ÷ 1000. A device delivering 100 mW/cm² for 60 seconds delivers 6 J/cm².
Wavelength (nm): determines penetration depth and chromophore targeting.
Treatment frequency and course length: most clinical protocols run 3–5 sessions per week for 2–8 weeks depending on the indication.
The biphasic dose response is well-documented: low to moderate doses stimulate healing and anti-inflammatory responses, while excessive doses inhibit or damage tissue. Small adjustments to irradiance or exposure time can flip PBM from stimulatory to inhibitory, which is why practitioners calibrate devices by matching published irradiance and fluence values for the target tissue.
Application
Typical irradiance (mW/cm²)
Typical fluence (J/cm²)
Session length
Frequency
Superficial skin / wound
10–30
1–4
1–5 min
Daily to 5×/week
Musculoskeletal / joint
50–150
4–20
5–10 min
3–5×/week
Transcranial (neurological)
10–100 (at scalp)
5–20
10–20 min
3–5×/week
These ranges reflect parameters reported across published studies and are not a prescription for any individual. Actual protocols should be designed in consultation with a clinician familiar with PBM.
Pro Tip:When reading a device spec sheet, prioritise clearly stated irradiance at the treatment distance (not at the LED surface), listed wavelengths, and independently tested output figures. Marketing language like “powerful” or “clinical-grade” without a stated mW/cm² figure at distance tells you nothing useful about therapeutic dose.
Stanford Medicine clinicians note that device strength and dosing determine effect size, and that clinical-grade devices with documented output are far more likely to reproduce study results than generic consumer gadgets.
Where not to use red and near-infrared light
PBM has a strong safety record when used correctly, but there are clear situations where it should not be applied without specialist input, and a few where it should not be applied at all.
Absolute and conditional contraindications:
Eyes: never apply red or near-infrared light directly to the eyes without appropriate protective eyewear. Retinal damage is a real risk; most clinical devices come with goggles and their use is non-negotiable.
Known or suspected malignant lesions: current consensus is to avoid treating directly over a known cancer site without specialist oncology input. The concern is theoretical (PBM’s pro-proliferative effects on healthy cells) but the precaution is standard practice.
Pregnancy: insufficient safety data exists for foetal exposure; avoid treating the abdomen and lower back during pregnancy.
Photosensitising medications: drugs including tetracyclines, fluoroquinolones, and some NSAIDs increase photosensitivity. Consult a prescribing clinician before starting PBM.
Active infection: PBM over an active bacterial or viral infection site may stimulate local tissue in ways that are not yet well characterised; seek medical advice first.
Recent corticosteroid injections: avoid treating an area within 2–4 weeks of a steroid injection; the tissue response may be altered.
Thyroid gland: some practitioners avoid direct treatment over the thyroid due to its sensitivity to stimulation; this is a precautionary rather than evidence-based restriction.
Common side effects reported in clinical literature include transient redness at the treatment site and a temporary increase in pain or sensitivity in the first 24–48 hours, particularly in people with significant inflammation. Both typically resolve without intervention. The Cleveland Clinic notes that some individuals experience increased inflammation or redness, particularly with higher doses.
Safety note: PBM is widely safe and non-invasive when used correctly, but it works best as part of a broader clinical plan. Clinician oversight reduces risk and improves outcomes — particularly for people managing active disease, taking multiple medications, or using devices at home without professional guidance.
Understanding the science is one thing. Knowing how to select a device, design a protocol, and integrate PBM into clinical or home care is where most people get stuck.
Define your target tissue first. Superficial skin conditions call for red wavelengths (630–660 nm); joint, muscle, and nerve targets need near-infrared (810–940 nm); many conditions benefit from both. Match the device to the tissue, not the other way around.
Check irradiance at treatment distance. A device that delivers 200 mW/cm² at the LED surface but only 20 mW/cm² at 10 cm is a very different therapeutic tool. Ask for or look up the irradiance specification at the distance you will actually be treating from.
Look for published dosing data. Reputable devices are designed to match the irradiance and fluence ranges used in peer-reviewed studies. If a manufacturer cannot point you to the clinical literature their protocol is based on, that is a meaningful gap.
Choose the right form factor. Flexible LED pads conform to body contours and are well-suited to joints, the lower back, and areas that are difficult to treat with a flat panel. Panels work well for larger surface areas and seated or lying treatments. Lifespan Dynamics offers both formats, developed in collaboration with clinical researchers including Professor Sungkyoo Lim, for clinical and at-home use.
Plan a treatment course, not a single session. Most clinical protocols involve multiple sessions per week over several weeks. A single session may produce acute relief but is unlikely to produce lasting anti-inflammatory changes. Build a schedule and stick to it.
Involve a clinician, especially for active disease. Physiotherapists, sports medicine doctors, and integrative GPs in Australia are increasingly familiar with PBM. A clinician can help you match a published protocol to your specific condition and monitor your response. The light therapy home treatment guide covers safe at-home use in detail.
Check Australian regulatory status. Therapeutic devices in Australia are regulated by the Therapeutic Goods Administration (TGA). Look for devices that are listed or registered with the TGA, or that are supplied by companies with documented compliance processes.
Pro Tip:To replicate a clinical protocol at home, find the study’s irradiance (mW/cm²) and fluence (J/cm²) values, then calculate the session time your device needs to deliver that fluence at its stated irradiance. If your device’s irradiance is lower than the study’s, you need a longer session — not a stronger belief that it will work.
Where PBM stands right now: a balanced verdict
PBM is not a fringe therapy. It has a peer-reviewed mechanistic basis, guideline adoption in at least one indication (oral mucositis), and a growing body of randomised controlled trial data for pain and wound healing. The evidence hierarchy looks like this:
Still largely preclinical: systemic immune modulation as a standalone treatment, visceral applications.
For Australian clinicians, the practical implication is straightforward: PBM is a reasonable adjunct therapy for pain and wound care, with a safety profile that makes it low-risk to trial in appropriate patients. For consumers, the message is similar but with an added caution: the device you choose and the protocol you follow matter enormously. A well-dosed session with a clinical-grade device is not the same as ten minutes under a cheap LED panel.
The applications overview at Lifespan Dynamics maps the evidence to specific conditions, which is a useful reference when deciding whether PBM is appropriate for a particular situation.
Key takeaways
Photobiomodulation produces measurable anti-inflammatory effects by activating cytochrome c oxidase in mitochondria, increasing ATP, modulating NF-κB signalling, and shifting cytokine profiles toward resolution — with the strongest clinical evidence in pain management, wound healing, and oral mucositis.
Point
Details
Core mechanism
PBM activates cytochrome c oxidase, increases ATP, and suppresses pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6.
Wavelength selection
Red (630–700 nm) targets superficial tissue; near-infrared (700–1100 nm) reaches muscle, joint, and deeper structures.
Dose is critical
The biphasic dose response means both underdosing and overdosing reduce effectiveness; match irradiance and fluence to published study parameters.
Safety first
Avoid direct eye exposure, treatment over malignant lesions, and use during pregnancy; consult a clinician for active disease.
Lifespan Dynamics devices
Lifespan Dynamics offers clinical and at-home LED pads and panels with documented wavelengths and irradiance, developed with clinical researchers for inflammation reduction and pain relief.
A practitioner’s perspective on PBM in Australia
What strikes me most about photobiomodulation, having followed the research closely, is how consistently the science holds up when the dosing is right — and how consistently it disappoints when it is not. The mechanism is not mysterious. Light hits a mitochondrial enzyme, ATP goes up, inflammatory signalling shifts. That chain is reproducible across species, cell types, and clinical settings. The variable is almost always the device or the protocol, not the biology.
What I think gets underestimated in Australia is the gap between what a well-designed clinical protocol can achieve and what most people experience with entry-level consumer devices. The research that excites clinicians uses irradiance values and fluence ranges that many consumer products simply do not deliver. That is not a reason to dismiss PBM. It is a reason to be specific about what you are using and why.
The other thing worth saying plainly: PBM works best alongside other care, not instead of it. For someone managing rheumatoid arthritis, chronic low back pain, or a slow-healing wound, PBM can meaningfully reduce the inflammatory burden and accelerate recovery. But it is an adjunct, not a replacement for medical management. The clinicians I respect most in this space use it that way — as a tool that extends what they can offer, not as a standalone answer.
If you are considering PBM for yourself or a patient, start with the evidence for your specific indication, match the protocol to a published study, and choose a device that can actually deliver the required dose. The science will do the rest.
Lifespan Dynamics devices: where to start in Australia
If you have read this far, you understand that the anti-inflammatory effects of red and near-infrared light are real, mechanism-based, and clinically supported — and that the device you choose determines whether you actually access those effects.
Lifespan Dynamics designs LED pads and panels for both clinical and at-home use, with wavelengths and irradiance specifications grounded in the clinical literature. Devices like the CelLED Pro Mini tri-wave pad deliver 660 nm, 850 nm, and 940 nm simultaneously, covering superficial and deep tissue targets in a single flexible, body-conforming format. Every device in the range is developed in collaboration with clinical researchers, including Professor Sungkyoo Lim, so the specs you see on the product page correspond to the parameters used in peer-reviewed protocols.
For those managing chronic inflammation, joint pain, or slow-healing tissue, the inflammation reduction device range is a practical starting point. If pain relief is the primary goal, the pain relief applications page maps specific device options to clinical indications. Before purchasing, consult an Australian health practitioner familiar with PBM to confirm the right protocol for your condition.
Useful sources
The following primary sources and reviews underpin the evidence discussed in this article:
Mechanisms and applications of the anti-inflammatory effects of photobiomodulation (PMC, Hamblin 2017) — systematic review; foundational reference on chromophores, mechanisms, and clinical applications.
Immunomodulatory effects of photobiomodulation: a comprehensive review (PMC) — covers NF-κB modulation, systemic effects, and clinical niches.
The anti-inflammatory effects of photobiomodulation are mediated by cytokines: evidence from a mouse model of inflammation (Frontiers in Neuroscience, 2023) — animal model; cytokine-level mechanistic data.
Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomised clinical trials (Springer Nature, 2025) — umbrella review of RCTs; covers guideline adoption and evidence hierarchy.
LED Light Therapy: how it works, colours, benefits and risks (Cleveland Clinic) — patient-facing clinical summary; useful for side effects and practical guidance.
Red light therapy: what the research says (Scientific American) — accessible science journalism covering emerging hypotheses including the cellular water mechanism.
Stanford Medicine insights on red light therapy — clinical perspective on device quality and dosing standards.
Red light (approximately 630–700 nm) and near-infrared light (approximately 700–1100 nm) are the wavelengths with the strongest evidence for anti-inflammatory effects, acting primarily through cytochrome c oxidase activation in mitochondria.
What does the anti-inflammatory light effect actually mean?
It refers to the measurable reduction in pro-inflammatory cytokines (including TNF-α, IL-1β, and IL-6) and the increase in anti-inflammatory mediators (including IL-10) that follows exposure to red or near-infrared light at therapeutic doses.
Where should you not apply red light therapy?
Avoid applying red or near-infrared light directly to the eyes without protective goggles, over known or suspected malignant lesions without specialist input, to the abdomen during pregnancy, or over areas recently injected with corticosteroids.
What are the downsides of infrared light therapy?
The most common side effects are transient redness and a temporary increase in pain or sensitivity at the treatment site within the first 24–48 hours. Overdosing — delivering too much irradiance or fluence — can inhibit rather than stimulate healing due to the biphasic dose response.
Does light therapy actually work for inflammation?
Yes, within the right dose parameters and for well-evidenced indications. The strongest clinical evidence supports PBM for musculoskeletal pain, wound healing, and oral mucositis; emerging evidence covers neuroinflammation and autoimmune conditions. Lifespan Dynamics devices are designed to deliver the irradiance and wavelengths used in peer-reviewed protocols, making them a reliable option for both clinical and at-home use.
Anti-inflammatory light effect explained: the science guide
The anti-inflammatory light effect is photobiomodulation (PBM): the use of red and near-infrared light, typically in the 600–1100 nm range, to shift cell biochemistry away from inflammation and toward repair. It is not heat therapy, and it is not a cosmetic gimmick. At the right dose, specific wavelengths activate mitochondrial proteins, increase ATP output, and suppress the signalling molecules that drive chronic inflammation.
Here is what that means in practice:
Table of Contents
What is the anti-inflammatory light effect, exactly?
Photobiomodulation is the formal scientific term for what most people call red light therapy or low-level laser therapy (LLLT). The phrase “anti-inflammatory light effect” describes one of PBM’s most clinically significant outcomes: the measurable reduction in pro-inflammatory signalling that follows exposure to red or near-infrared light at non-thermal intensities.
The wavelength bands that produce this effect sit roughly between 600 nm and 1100 nm. Devices that deliver PBM include low-level lasers, LED panels, and flexible LED pads. Each format can produce therapeutic irradiance; the key variable is whether the device actually delivers the stated output at the treatment distance, not the form factor itself.
Two researchers whose work anchors the evidence base are worth knowing. Michael R. Hamblin, formerly of the Wellman Center for Photomedicine at Harvard, has authored or co-authored hundreds of peer-reviewed PBM papers, including foundational mechanistic reviews. A 2023 paper published in Frontiers in Neuroscience demonstrated cytokine-level anti-inflammatory effects in animal models, adding mechanistic weight to earlier clinical observations.
This article covers mechanisms, evidence quality, dosing parameters, safety, and practical device selection for Australian clinicians and informed consumers. It does not make cosmetic claims unsupported by clinical evidence.
Which molecules actually absorb the light?
Light cannot change cell behaviour unless something inside the cell absorbs it first. Those absorbing molecules are called chromophores, and identifying them is what separates PBM science from speculation.
Cytochrome c oxidase is the primary chromophore and the most important one to understand. It sits in the inner mitochondrial membrane as part of Complex IV of the electron transport chain — essentially the final step in the process your cells used to generate energy. When red or near-infrared photons are absorbed by cytochrome c oxidase, the enzyme’s activity increases, driving more ATP production and reducing the accumulation of reactive oxygen species (ROS) that would otherwise trigger inflammatory signalling. Think of it as unchaining a slightly sluggish engine: the light removes a brake on energy production.
Beyond cytochrome c oxidase, several other chromophores contribute:
Chromophore absorption is wavelength-specific. Cytochrome c oxidase absorbs most strongly in two bands: around 630–680 nm (red) and 800–880 nm (near-infrared). This is why PBM devices targeting deep tissue tend to use wavelengths in those ranges rather than arbitrary choices.
How absorbed light changes your cell biochemistry
The photon hits cytochrome c oxidase. What happens next is a cascade, not a single event, and understanding the sequence explains why PBM can reduce inflammation in tissues the light never directly touches.
Step one: mitochondrial stimulation. Increased cytochrome c oxidase activity accelerates the electron transport chain, producing more ATP. Cells with more ATP available can repair membranes, synthesise proteins, and regulate ion gradients more effectively — all processes that are compromised in inflamed or injured tissue.
Step two: the ROS signal. A brief, low-level burst of reactive oxygen species follows photon absorption. This sounds counterintuitive — ROS are usually framed as damaging — but at low concentrations they act as signalling molecules. This transient ROS pulse activates transcription factors including NF-κB and MAPK. PBM modulates NF-κB activation, and in pro-inflammatory tissue environments, that modulation tends to suppress rather than amplify the inflammatory response. The distinction matters: the same pathway that drives inflammation when chronically activated can be reset toward resolution by a well-dosed PBM stimulus.
Step three: cytokine shifts. The downstream result of NF-κB and MAPK modulation is a measurable change in cytokine expression. Pro-inflammatory mediators including TNF-α, IL-1β, IL-6, and IL-18 are reduced; anti-inflammatory cytokines including IL-10 and TGF-β increase. These are not theoretical predictions — they have been measured in animal models and, increasingly, in human tissue samples.
Step four: systemic spread. Local PBM treatment does not stay local. Circulating cytokines and neural reflexes carry the anti-inflammatory signal systemically, which explains why treating one limb sometimes produces measurable effects elsewhere. This systemic dimension is one of the more surprising findings in PBM research and one of the reasons clinical protocols are becoming more sophisticated.
Key biochemical changes at a glance:
Why wavelength determines how deep the light reaches
Not all wavelengths behave the same way inside tissue. The physics of light scattering and absorption by water, haemoglobin, and melanin create a penetration window that is directly relevant to clinical decision-making.
Red light is absorbed more readily by haemoglobin and melanin, which limits its reach to superficial layers. Near-infrared light scatters less and penetrates further, making it the preferred choice for joint, muscle, and neurological targets. For skin conditions and superficial wound healing, red wavelengths around 630–660 nm are well-supported. For deeper structures — a knee joint, a lumbar muscle, or transcranial applications — 810–850 nm and above is where the evidence sits.
Devices that combine multiple wavelengths (sometimes called tri-wave devices) allow a single treatment session to address both superficial and deeper tissue simultaneously. The CelLED Pro Mini tri-wave pad from Lifespan Dynamics, for example, delivers 660 nm, 850 nm, and 940 nm in one flexible pad — covering the red band for surface tissue and two NIR bands for deeper penetration.
Pro Tip: When comparing devices, check whether the stated wavelength is the peak emission wavelength or the full-width half-maximum (FWHM) range. A device labelled “850 nm” should emit most of its energy within a narrow band around that peak, not across a broad spectrum that dilutes the therapeutic dose.
For a detailed comparison of red versus near-infrared applications, this wavelength guide is worth reading before choosing a device.
What does the clinical evidence actually show?
The evidence base for PBM’s anti-inflammatory effects spans in vitro cell studies, animal models, and human clinical trials. Quality and confidence vary by indication, so it is worth being specific.
Animal models have produced some of the clearest mechanistic data. A 2023 Frontiers in Neuroscience study demonstrated that red and near-infrared PBM downregulated IL-1β, IL-18, and upregulated IL-10 in a mouse inflammation model following ten days of exposure. Inflammasome modulation — the suppression of the protein complexes that trigger IL-1β and IL-18 release — is a plausible mechanism for the observed reductions in tissue inflammation and improved healing.
Human clinical evidence is strongest for three indications:
Neuroinflammation and transcranial PBM are areas of active research with promising early data, but not yet the volume of randomised controlled trials needed for strong clinical recommendations.
Michael R. Hamblin’s body of work, including his 2017 PMC review on mechanisms and applications of PBM’s anti-inflammatory effects, remains one of the most cited starting points for understanding the evidence hierarchy. His framing of cytochrome c oxidase as the primary chromophore and the biphasic dose response as a central clinical challenge has shaped how researchers and clinicians approach protocol design.
Why dose matters more than most people realise
The single most common reason PBM fails to produce results is incorrect dosing. Too little irradiance and the photons do not reach therapeutic threshold; too much and the biphasic dose response tips from stimulatory to inhibitory.
Key parameters to understand:
The biphasic dose response is well-documented: low to moderate doses stimulate healing and anti-inflammatory responses, while excessive doses inhibit or damage tissue. Small adjustments to irradiance or exposure time can flip PBM from stimulatory to inhibitory, which is why practitioners calibrate devices by matching published irradiance and fluence values for the target tissue.
These ranges reflect parameters reported across published studies and are not a prescription for any individual. Actual protocols should be designed in consultation with a clinician familiar with PBM.
Pro Tip: When reading a device spec sheet, prioritise clearly stated irradiance at the treatment distance (not at the LED surface), listed wavelengths, and independently tested output figures. Marketing language like “powerful” or “clinical-grade” without a stated mW/cm² figure at distance tells you nothing useful about therapeutic dose.
Stanford Medicine clinicians note that device strength and dosing determine effect size, and that clinical-grade devices with documented output are far more likely to reproduce study results than generic consumer gadgets.
Where not to use red and near-infrared light
PBM has a strong safety record when used correctly, but there are clear situations where it should not be applied without specialist input, and a few where it should not be applied at all.
Absolute and conditional contraindications:
Common side effects reported in clinical literature include transient redness at the treatment site and a temporary increase in pain or sensitivity in the first 24–48 hours, particularly in people with significant inflammation. Both typically resolve without intervention. The Cleveland Clinic notes that some individuals experience increased inflammation or redness, particularly with higher doses.
For a thorough contraindications checklist tailored to Australian consumers and clinicians, the light therapy contraindications assessment guide is a practical starting point.
How to put this into practice in Australia
Understanding the science is one thing. Knowing how to select a device, design a protocol, and integrate PBM into clinical or home care is where most people get stuck.
Define your target tissue first. Superficial skin conditions call for red wavelengths (630–660 nm); joint, muscle, and nerve targets need near-infrared (810–940 nm); many conditions benefit from both. Match the device to the tissue, not the other way around.
Check irradiance at treatment distance. A device that delivers 200 mW/cm² at the LED surface but only 20 mW/cm² at 10 cm is a very different therapeutic tool. Ask for or look up the irradiance specification at the distance you will actually be treating from.
Look for published dosing data. Reputable devices are designed to match the irradiance and fluence ranges used in peer-reviewed studies. If a manufacturer cannot point you to the clinical literature their protocol is based on, that is a meaningful gap.
Choose the right form factor. Flexible LED pads conform to body contours and are well-suited to joints, the lower back, and areas that are difficult to treat with a flat panel. Panels work well for larger surface areas and seated or lying treatments. Lifespan Dynamics offers both formats, developed in collaboration with clinical researchers including Professor Sungkyoo Lim, for clinical and at-home use.
Plan a treatment course, not a single session. Most clinical protocols involve multiple sessions per week over several weeks. A single session may produce acute relief but is unlikely to produce lasting anti-inflammatory changes. Build a schedule and stick to it.
Involve a clinician, especially for active disease. Physiotherapists, sports medicine doctors, and integrative GPs in Australia are increasingly familiar with PBM. A clinician can help you match a published protocol to your specific condition and monitor your response. The light therapy home treatment guide covers safe at-home use in detail.
Check Australian regulatory status. Therapeutic devices in Australia are regulated by the Therapeutic Goods Administration (TGA). Look for devices that are listed or registered with the TGA, or that are supplied by companies with documented compliance processes.
Pro Tip: To replicate a clinical protocol at home, find the study’s irradiance (mW/cm²) and fluence (J/cm²) values, then calculate the session time your device needs to deliver that fluence at its stated irradiance. If your device’s irradiance is lower than the study’s, you need a longer session — not a stronger belief that it will work.
Where PBM stands right now: a balanced verdict
PBM is not a fringe therapy. It has a peer-reviewed mechanistic basis, guideline adoption in at least one indication (oral mucositis), and a growing body of randomised controlled trial data for pain and wound healing. The evidence hierarchy looks like this:
For Australian clinicians, the practical implication is straightforward: PBM is a reasonable adjunct therapy for pain and wound care, with a safety profile that makes it low-risk to trial in appropriate patients. For consumers, the message is similar but with an added caution: the device you choose and the protocol you follow matter enormously. A well-dosed session with a clinical-grade device is not the same as ten minutes under a cheap LED panel.
The applications overview at Lifespan Dynamics maps the evidence to specific conditions, which is a useful reference when deciding whether PBM is appropriate for a particular situation.
Key takeaways
Photobiomodulation produces measurable anti-inflammatory effects by activating cytochrome c oxidase in mitochondria, increasing ATP, modulating NF-κB signalling, and shifting cytokine profiles toward resolution — with the strongest clinical evidence in pain management, wound healing, and oral mucositis.
A practitioner’s perspective on PBM in Australia
What strikes me most about photobiomodulation, having followed the research closely, is how consistently the science holds up when the dosing is right — and how consistently it disappoints when it is not. The mechanism is not mysterious. Light hits a mitochondrial enzyme, ATP goes up, inflammatory signalling shifts. That chain is reproducible across species, cell types, and clinical settings. The variable is almost always the device or the protocol, not the biology.
What I think gets underestimated in Australia is the gap between what a well-designed clinical protocol can achieve and what most people experience with entry-level consumer devices. The research that excites clinicians uses irradiance values and fluence ranges that many consumer products simply do not deliver. That is not a reason to dismiss PBM. It is a reason to be specific about what you are using and why.
The other thing worth saying plainly: PBM works best alongside other care, not instead of it. For someone managing rheumatoid arthritis, chronic low back pain, or a slow-healing wound, PBM can meaningfully reduce the inflammatory burden and accelerate recovery. But it is an adjunct, not a replacement for medical management. The clinicians I respect most in this space use it that way — as a tool that extends what they can offer, not as a standalone answer.
If you are considering PBM for yourself or a patient, start with the evidence for your specific indication, match the protocol to a published study, and choose a device that can actually deliver the required dose. The science will do the rest.
Lifespan Dynamics devices: where to start in Australia
If you have read this far, you understand that the anti-inflammatory effects of red and near-infrared light are real, mechanism-based, and clinically supported — and that the device you choose determines whether you actually access those effects.
Lifespan Dynamics designs LED pads and panels for both clinical and at-home use, with wavelengths and irradiance specifications grounded in the clinical literature. Devices like the CelLED Pro Mini tri-wave pad deliver 660 nm, 850 nm, and 940 nm simultaneously, covering superficial and deep tissue targets in a single flexible, body-conforming format. Every device in the range is developed in collaboration with clinical researchers, including Professor Sungkyoo Lim, so the specs you see on the product page correspond to the parameters used in peer-reviewed protocols.
For those managing chronic inflammation, joint pain, or slow-healing tissue, the inflammation reduction device range is a practical starting point. If pain relief is the primary goal, the pain relief applications page maps specific device options to clinical indications. Before purchasing, consult an Australian health practitioner familiar with PBM to confirm the right protocol for your condition.
Useful sources
The following primary sources and reviews underpin the evidence discussed in this article:
FAQ
Which light wavelengths are anti-inflammatory?
Red light (approximately 630–700 nm) and near-infrared light (approximately 700–1100 nm) are the wavelengths with the strongest evidence for anti-inflammatory effects, acting primarily through cytochrome c oxidase activation in mitochondria.
What does the anti-inflammatory light effect actually mean?
It refers to the measurable reduction in pro-inflammatory cytokines (including TNF-α, IL-1β, and IL-6) and the increase in anti-inflammatory mediators (including IL-10) that follows exposure to red or near-infrared light at therapeutic doses.
Where should you not apply red light therapy?
Avoid applying red or near-infrared light directly to the eyes without protective goggles, over known or suspected malignant lesions without specialist input, to the abdomen during pregnancy, or over areas recently injected with corticosteroids.
What are the downsides of infrared light therapy?
The most common side effects are transient redness and a temporary increase in pain or sensitivity at the treatment site within the first 24–48 hours. Overdosing — delivering too much irradiance or fluence — can inhibit rather than stimulate healing due to the biphasic dose response.
Does light therapy actually work for inflammation?
Yes, within the right dose parameters and for well-evidenced indications. The strongest clinical evidence supports PBM for musculoskeletal pain, wound healing, and oral mucositis; emerging evidence covers neuroinflammation and autoimmune conditions. Lifespan Dynamics devices are designed to deliver the irradiance and wavelengths used in peer-reviewed protocols, making them a reliable option for both clinical and at-home use.
Recommended